Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library

Items where at least one author is a Healthy Skepticism member

Page 2 of 3 pages  < 1 2 3 > 

Healy D, Herxheimer A, Menkes D.
Antidepressants and Violence: Problems at the Interface of Medicine and Law
PLoS 2006 Sep 13

Korczak V.
What's wrong with pushing pills?
New Matilda 2006 Sep 8

Harvey K.
Drug companies' free lunches have expensive side-effects
New Matilda 2006 Aug 4

Mansfield PR.
Another way to tame the monster
BMJ 2006 Jul 22;333:(7560):202

Mansfield PR.
A more comprehensive alternative
PLoS Med 2006 Jul 18;3:(7):306

Lexchin J.
Risks and benefits of the profit motive in the pharmaceutical industry
Agora Vox 2006 Jul 11

Mansfield PR.
Rapid responses: A more comprehensive and achievable alternative
BMJ 2006 Jul 8;333:

Lexchin J, Williams R, Marion J.
Rebuttal: are drugs too expensive in Canada?
Can Fam Physician 2006 Jul;52:841-2,:

Fugh-Berman A, Alladin K, Chow J.
Advertising in Medical Journals: Should Current Practices Change?
PLoS Med 2006 Jun 27;3:(6):e130

Lexchin J, Light DW.
Commercial influence and the content of medical journals.
BMJ 2006 Jun 17;332:(7555):1444-7

Mira AJ, Isely W, McDonnell M, Huch KM, Whittle HM, Nugent TJ, Lack DZ
Readers' Responses to "Physicians on the Take"
MedGenMed 2006 May 12;

McConnell M.
An open letter to Healthy Skepticism:
2006 May 3

Lexchin J.
Are drugs too expensive in Canada? Yes
Can Fam Physician. 2006 May 01;52:573-6, 578-81

Lexchin J.
Who Should Own the Presses?
Israeli Journal of Emergency Medicine 2006 May;6:(2):3-5

Biron P, Mintzes B, Lexchin J.
Questions about Adderall XR.
CMAJ 2006 Apr 25;174:(9):1303-4

A Collection of Articles on Disease Mongering
PLoS Medicine ( Public Library of Science) 2006 Apr 11

Henry D, Moynihan R.
Inaugural Conference on Disease-Mongering 2006 Apr 11

Lexchin J.
Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices
CMAJ 2006 Apr 11;174:(8):1120-1

Mansfield PR.
Universal Hepatitis-B Vaccination in India: A Questionable Strategy
BMJ 2006 Apr 7;302:

Roughead EE, Lexchin J.
Adverse drug events: counting is not enough, action is needed.
Med J Aust 2006 Apr 3;184:(7):315-6

Jureidini J.
Systematic checks can avert crisis from adverse drug reactions
The Australian Newspaper 2006 Apr 1,5744,18666410%255E23289,00.html

Mansfield PR, Phadke A, Kale A.
Blanket hepatitis B vaccination is questionable in India
BMJ 2006 Apr 1;332:(7547):976

Lexchin J.
Bigger and Better: How Pfizer Redefined Erectile Dysfunction
PLoS Med 2006 Apr;3:(4):

Almasi E, Stafford R, Kravitz RL, Mansfield PR.
What Are the Public Health Effects of Direct-to-Consumer Drug Advertising?
PLoS Medicine 2006 Mar 28;3:(3):e145

Lexchin J .
Withdrawals of drugs for safety reasons: How do regulators decide if they are too unsafe?
Reaction Bulletin 2006 Feb 1;236:

Lexchin J.
Is there still a role for spontaneous reporting of adverse drug reactions?
CMAJ 2006 Jan 17;174:(2):191-2

Tonkin AL, Taverner D, Latte J, Doecke C.
The Effect of an Interactive Tutorial on the Prescribing Performance of Senior Medical Students
Med Educ. 2006;

Mansfield PR, Lexchin J, Wen LS, Grandori L, McCoy CP, Hoffman JR, Ramos J, Jureidini JN.
Educating Health Professionals about Drug and Device Promotion: Advocates' Recommendations
PLoS Med 2006;3:(11):e451

Mansfield P.
Industry-Sponsored Research: A More Comprehensive Alternative.
PLoS Med 2006;3:(10):e463

Cohen JC, Illingworth P, Schuklenk U, Eds .
The Power of Pills
London: Pluto Press 2006

Jureidini J, Tonkin A.
Overuse of antidepressant drugs for the treatment of depression.
CNS Drugs 2006;20:(8):623-32

Jureidini JN, Mansfield PR.
The scope of the problem of the relationship between drug companies and doctors
Maitra B, Timimi S. Critical Voices in Child and Adolescent Mental Health London: Free Association Books 2006

Light D.
Basic research funds to discover important new drugs: who contributes how much?
Burke MA, De Francisco A. Monitoring Financial Flows for Health Research 2005: Behind the Global Numbers Geneva: Global Forum for Health Research 2006

Harvey K.
Submission to ACCC re: Application A90994-6 by Medicines Australia re revised Code of Conduct [15th Ed]
Medreach ( ) 2005 Dec 14

Norris P, Herxheimer A, Lexchin J, Mansfield P.
Drug Promotion: What we know, what we have yet to learn.
Geneva: World Health Organisation and Health Action International 2005 Dec

Light D, Lexchin J.
US drug prices not Canada's fault, study says
York University 2005 Oct 22

Light DW, Lexchin J.
Foreign free riders and the high price of US medicines.
BMJ 2005 Oct 22;331:(7522):958-60

Goodman, B
Pictures at an Exhibition: The 2005 American Academy of Family Practice Annual Meeting, San Francisco, California
No Free Lunch 2005 Oct 2

Lexchin J.
Commentary: Nesiritide and Lessons Unlearned
Israeli Journal of Emergency Medicine 2005 Oct;5:(4):69-72

Mansfield PR.
Response to Jeffrey Mann: Clinical trials never produce certainty
BMJ 2005 Sep 16;331:

Mansfield PR.
Celecoxib causes excess cardiovascular events and illustrates the folly of allowing drug sellers too much power.
BMJ 2005 Sep 10;331:

Mansfield PR.
Banning all drug promotion is the best option pending major reforms.
J Bioethical Inquiry 2005;2:(2):16-22

Mansfield PR, Tonkin AL, Jureidini JN.
Fluoxetine for depressed adolescents: harms likely to exceed benefits
BMJ 2005 May 28;330:

Harvey KJ, Vitry AI., Aroni R, Ballenden N, Faggotter R.
Pharmaceutical advertisements in prescribing software: an analysis
MJA 2005 Jul 18;183:(2):75-79

Mansfield PR.
Response to Pfizer
BMJ 2005 Jun 27;

Toop L, Richards D, Dowell T.
Response to Maubach and Hoek's paper on GP attitudes to DTCA
N Z Med J. 2005 Jun 24;118:(1217):U1543

Stocks N, Allan J, Mansfield PR.
Management of hyperlipidaemia.
Aust Fam Physician 2005 Jun;34:(6):447-53

Mintzes B, Barer M, Lexchin J, Bassett KL.
Introduction of direct-to-consumer advertising of prescription drugs in Canada: an opinion survey on regulatory policy.
Res Social Adm Pharm 2005 Jun;1:(2):310-30

Dinant G-J, Mansfield P.
Van zoete koek naar gezonde scepsis: De houding van huisartsen tegenover geneesmiddelenreclame
Huisarts Wet 2005 May 2;48:(6):304-307

Shann F.
Non-specific effects of vaccination: vaccines have non-specific (heterologous) effects.
BMJ 2005 Apr 9;330:(7495):844

Mansfield PR, Vitry A.
Rofecoxib withdrawal.
Australian Prescriber 2005 Apr;28:(2):30

Lexchin J.
Drug withdrawals from the Canadian market for safety reasons, 1963-2004.
CMAJ 2005 Mar 15;172:(6):765-7

Raven M, Rogers W, Jureidini J.
Partnerships between academic psychiatry and the pharmaceutical industry.
Australas Psychiatry 2005 Mar;13:(1):83-4

Mansfield PR.
Beliefs and plans of GP registrars before and after a 90 minute talk about drug promotion
Unpublished 2005 Feb 25;

Mansfield PR, Vitry AI, Wright JM.
Withdraw all COX-2-selective drugs.
Med J Aust 2005 Feb 21;182:(4):197

Lexchin J.
Prescribing errors
CMAJ 2005 Jan 18;172:(2):

Lexchin J, Cassels A.
Does the C in CME stand for "Continuing" or "Commercial"?
CMAJ 2005 Jan 18;172:(2):160-2

Mansfield PR, Mintzes B, Richards D, Toop L.
Direct to consumer advertising.
BMJ 2005 Jan 1;330:(7481):5-6

Lexchin JR.
Implications of pharmaceutical industry funding on clinical research.
Ann Pharmacother 2005 Jan;39:(1):194-7

Jureidini JN, Tonkin A.
Suicide and antidepressants in children (editorial)
Australian Prescriber 2005;28:110-1

Mansfield PR, Raven MK, Jureidini JN.
Depressed youth, suicidality and antidepressants
MJA 2005;183:(5):275-276

Lexchin J.
Intellectual propety rights and the Canadian pharmaceutical marketplace: Where do we go from here?
International Journal of Health Services 2005;35:(2):237 - 256,2,13;journal,9,146;linkingpublicationresults,1:300313,1

Mintzes B, Lexchin J.
Do higher drug costs lead to better health?
Can J Clin Pharmacol 2005 Win;12:(1):e22-7

Mansfield P.
Accepting what we can learn from advertising's mirror of desire.
BMJ 2004 Dec 18;329:(7480):1487-8

Jureidini J, Tonkin A, Mansfield PR.
TADS study raises concerns.
BMJ 2004 Dec 4;329:(7478):1343-4

Light DW, Lexchin J.
Will lower drug prices jeopardize drug research? A policy fact sheet
Am J Bioeth 2004 Winter;4:(1):1-4

Mansfield PR.
Safety Query.
Australian Doctor Weekly 2004 Nov 17

Allen K, Mansfield P.
Changing attitudes to 'the change'.
Aust Fam Physician 2004 Nov;33:(11):939-40

Mansfield PR, Henry D.
Misleading drug promotion--no sign of improvements.
Pharmacoepidemiol Drug Saf 2004 Nov;13:(11):797-9

Mansfield PR.
Reform of incentives would help reduce harm from drug promotion
BMJ 2004 Oct 30;329:

Mansfield PR.
Reply to Stephen Black and Nicholas DeMartinis
2004 Oct 15;329:

Mansfield PR.
Banned drug's world of faceless victims
The Independent Weekly (Adelaide) 2004 Oct 10-16

Mansfield PR, Tonkin AL, Jureidini JN.
Antidepressants do less good than harm for children and adolescents
BMJ 2004 Oct 8;329:

Mansfield PR.
A 5 minute read re drug promotion: RCT
Poster presented at 8th World Congress on Clinical Pharmacology & Therapeutics (CPT2004) Brisbane 2004 Aug 1-6;

Toop L, Richards D.
Physicians' negative views of direct-to-consumer advertising (DTCA): the international evidence grows.
N Z Med J 2004 Jun 4;117:(1195):U905

Mansfield PR.
Clarification and Update for AdWatch on Nexium dialogue
BMJ 2004 Apr 30;328:

Rogers WA, Mansfield PR, Braunack-Mayer AJ, Jureidini JN.
The ethics of pharmaceutical industry relationships with medical students.
Med J Aust 2004 Apr 19;180:(8):411-4

Jureidini JN, Doecke CJ, Mansfield PR, Haby MM, Menkes DB, Tonkin AL.
Efficacy and safety of antidepressants for children and adolescents.
BMJ 2004 Apr 10;328:(7444):879-83

Timimi S, Moncrieff J, Jureidini J, Leo J, Cohen D, Whitfield C, Double D, Bindman J, Andrews H, Asen E, Bracken P, Duncan B, Dunlap M, Albert G, Green M, Greening T, Hill J, Huws R, Karon B, Kean B, McCubbin M, Miatra B, Mosher L, Parry S, DuBose Ravenel
A critique of the international consensus statement on ADHD.
Clin Child Fam Psychol Rev 2004 Mar;7:(1):59-63

Ong A, Mansfield PR.
Controversies: Should free drug samples be banned?
Australian Doctor Weekly 2004 Feb 6

Svensson S, Mansfield PR.
Escitalopram: superior to citalopram or a chiral chimera?
Psychother Psychosom 2004 Jan-Feb;73:(1):10-6

Mansfield P, Henry D, Tonkin A.
Single-enantiomer drugs: elegant science, disappointing effects.
Clin Pharmacokinet 2004;43:(5):287-90

Medawar C, Herxheimer A.
A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behaviour with paroxetine
The International Journal of Risk and Safety in Medicine 2004;16:(1):5-19,3,8;journal,12,26;linkingpublicationresults,1:103162,1;

Mansfield PR.
Healthy Skepticism's new AdWatch: understanding drug promotion.
Med J Aust 2003 Dec 1-15;179:(11-12):644-5

Jureidini J, Mansfield P, Menkes D.
The statin wars.
Lancet 2003 Nov 29;362:(9398):1855

Katz D, Mansfield P, Goodman R, Tiefer L, Merz J.
Psychological aspects of gifts from drug companies.
JAMA 2003 Nov 12;290:(18):2404-5

Carter H, Mansfield P.
Eye on ads.
Australian Doctor Weekly 2003 Nov 5

Moncrieff J, Double D.
Double blind random bluff.
Ment Health Today 2003 Nov;:24-6:

Mansfield PR.
Healthy scepticism.
Aust Fam Physician 2003 Oct;32:(10):777

Mansfield PR, Mintzes B.
Direct-to-consumer advertising is more profitable if it is misleading.
N Z Med J 2003 Sep 26;116:(1182):U610

Mintzes B, Barer ML, Kravitz RL, Bassett K, Lexchin J, Kazanjian A, Evans RG, Pan R, Marion SA.
How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA
CMAJ. 2003 Sep 2;169:(5):405-12

Mansfield PR.
Drug marketing deserves recognition
BMJ 2003 Aug 28;327:

Toop L, Richards D, Saunders B.
New Zealand deserves better. Direct-to-consumer advertising (DTCA) of prescription medicines in New Zealand: for health or for profit?
N Z Med J. 2003 Aug 22;116:(1180):U556

Mansfield PR.
Gifts must go
Australian Doctor Weekly 2003 Aug 21

Jureidini J, Mansfield P.
The journal and drug advertising.
Aust N Z J Psychiatry 2003 Aug;37:(4):495

Mansfield PR, Mak HK.
Drug reps: friend or foe?
Australian Doctor Weekly 2003 Jun 24

Mansfield PR.
Bribes for doctors: a gift for bioethicists?
Am J Bioeth 2003 Summer;3:(3):47-8

Fugh-Berman A.
"Bust enhancing" herbal products.
Obstet Gynecol 2003 Jun;101:(6):1345-9

Lexchin J, Bero LA, Djulbegovic B, Clark O.
Pharmaceutical industry sponsorship and research outcome and quality: systematic review.
BMJ 2003 May 31;326:(7400):1167-70

Mansfield PR.
Free offer for all BMJ readers from Healthy Skepticism
BMJ 2003 May 30;326:

Page 2 of 3 pages  < 1 2 3 > 


  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Click to Register

(read more)

Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts

If there is something you don't like, please tell us. If you like our work, please tell others.

You are going to have many difficulties. The smokers will not like your message. The tobacco interests will be vigorously opposed. The media and the government will be loath to support these findings. But you have one factor in your favour. What you have going for you is that you are right.
- Evarts Graham
When truth is unwelcome: the first reports on smoking and lung cancer.